Shots:
Verve to receive $60M up front incl. $35M in equity investment & is also eligible to receive an additional fee of ~$66M, $340M in development and commercial milestones along with royalties on net sales for any products resulting from the collaboration
Verve will accelerate the discovery, research, and preclinical development of a novel in vivo gene editing program for the target of interest with all program costs funded by Vertex. Vertex will lead the development, manufacturing, and commercialization of the program resulting from Verve’s research efforts.
The agreement expands Verve’s gene editing capabilities and pipeline to develop in vivo gene editing therapies for serious diseases
Ref: Vertex | Image: Vertex
